

# Auto-hydroxylation of FIH-1: an Fe(II), $\alpha$ -ketoglutarate-dependent human hypoxia sensor†

Yuan-Han Chen,<sup>ab</sup> Lindsay M. Comeaux,<sup>b</sup> Stephen J. Eyles<sup>c</sup> and Michael J. Knapp<sup>\*ab</sup>

Received (in Cambridge, UK) 29th May 2008, Accepted 10th July 2008

First published as an Advance Article on the web 11th August 2008

DOI: 10.1039/b809099h

**HIF-asparaginyl hydroxylase (FIH-1) normally couples O<sub>2</sub>-activation to hydroxylation of Asn<sup>803</sup> on the  $\alpha$ -subunit of the hypoxia-inducible factor (HIF $\alpha$ ), a key step in pO<sub>2</sub> sensing; in the absence of HIF $\alpha$ , O<sub>2</sub>-activation becomes uncoupled, leading to self-hydroxylation at Trp<sup>296</sup> and a purple Fe(III)–O–Trp chromophore—this alternative reactivity may affect human hypoxia sensing.**

Cellular responses to O<sub>2</sub> levels are central to human health, controlling processes such as angiogenesis and basal metabolism.<sup>1,2</sup> Tight regulation of O<sub>2</sub> is necessary, as while it is required for aerobic metabolism, an excess can lead to oxidative damage. In humans, the master regulator of O<sub>2</sub>-homeostasis is a transcription factor called the hypoxia-inducible factor (HIF), which is inactivated by HIF-asparaginyl hydroxylase (previously identified as FIH-1), a non-heme, Fe(II),  $\alpha$ -ketoglutarate ( $\alpha$ KG)-dependent dioxygenase.<sup>3–5</sup> While tight coupling between O<sub>2</sub>-activation and HIF-hydroxylation would be expected for optimal O<sub>2</sub> sensing, some  $\alpha$ KG-dependent dioxygenases exhibit uncoupled O<sub>2</sub>-activation. We establish here that FIH-1 self-hydroxylates in the absence of HIF, suggesting that uncoupling between O<sub>2</sub> and HIF may alter the activity levels of FIH-1.

HIF is a heterodimeric transcription factor, consisting of the HIF $\alpha$  monomer, which is regulated in response to pO<sub>2</sub>, and the ARNT monomer, which is insensitive with respect to pO<sub>2</sub>. Under the conditions of hypoxia (low pO<sub>2</sub>), HIF assembles the transcriptional co-activator, p300, upstream from HIF controlled genes, thereby promoting the expression of over 100 genes involved in iron transport, angiogenesis and basal metabolism.<sup>1,6</sup> The key intermolecular interactions are found between transcriptional machinery and the C-terminal domain of HIF $\alpha$ .<sup>7,8</sup> FIH-1 uses O<sub>2</sub> to hydroxylate the  $\beta$ -carbon of HIF $\alpha$ -Asn<sup>803</sup>,<sup>9</sup> preventing p300 from binding to HIF $\alpha$ , and thereby turning off gene expression in response to increasing pO<sub>2</sub>.

Although the sensing of pO<sub>2</sub> should require tight coupling between pO<sub>2</sub> and the hydroxylation of HIF $\alpha$ , the chemical mechanism of FIH-1 activity suggests that O<sub>2</sub> consumption

could be uncoupled from HIF-hydroxylation. In the consensus mechanism, HIF $\alpha$  binding displaces the axial H<sub>2</sub>O from the Fe(II)– $\alpha$ KG center, which opens up a coordination site for O<sub>2</sub> binding.<sup>10,11</sup> This leads to the formation of the Fe(IV)=O intermediate, but only when the HIF $\alpha$ -Asn<sup>803</sup> sidechain is nearby, ensuring that O<sub>2</sub>-activation only occurs when HIF $\alpha$  is present. However, spectroscopic studies suggest that the axial H<sub>2</sub>O in other members of the Fe(II),  $\alpha$ KG-dependent dioxygenases can be released, even in the absence of a prime substrate;<sup>12,13</sup> if this occurred on FIH-1, it would lead to uncoupling between O<sub>2</sub> and HIF $\alpha$ . It is notable that in activity assays of FIH-1 and many other members of the non-heme, Fe(II),  $\alpha$ KG-dependent dioxygenase superfamily, excess ascorbate was required for full activity, as this maintained the iron in the reduced state.<sup>10</sup>

In addition, a few members of this superfamily deactivate by auto-hydroxylation in the absence of a prime substrate. For example, aromatic residues within the active site of TauD (Tyr)<sup>14</sup> and TfdA (Trp)<sup>15</sup> are hydroxylated during uncoupling to generate an Fe(III) coordinated by an aromatic alcohol, suggesting that the electrophilic Fe(IV)=O species can oxidatively attack residues within  $\sim 10$  Å of it, to create new metal-binding ligands. The active site of FIH-1 contains three aromatic residues that, based upon these chemical precedents in bacterial enzymes, could be susceptible to hydroxylation.

To determine whether FIH-1 can auto-hydroxylate, apo-FIH (100  $\mu$ M in 50 mM HEPES, pH 7.50), FeSO<sub>4</sub> (500  $\mu$ M) and  $\alpha$ KG (500  $\mu$ M) were incubated anaerobically in a sealed cuvette for 1 h. The absorption spectrum was measured, and it showed a moderate-intensity absorption near 520 nm, which could be attributed to the Fe(II)– $\alpha$ KG charge transfer that would be expected for resting FIH-1.<sup>17</sup> The cuvette was then opened to air to introduce O<sub>2</sub>, with the reaction being monitored by a UV-vis spectrophotometer over 10 000 seconds. A new absorption band appeared at  $\lambda_{\text{max}} = 583$  nm ( $\epsilon_{583} = 3 \times 10^3$  M<sup>-1</sup> cm<sup>-1</sup>), which was consistent with the product of auto-hydroxylation: Fe(III) coordinated to an aromatic alcohol (Fig. 1). Negative controls, in which any individual component was omitted, showed that this chromophore required FIH-1, Fe(II), O<sub>2</sub> and  $\alpha$ KG for its formation.


Auto-hydroxylation in TauD leads to the formation of a hydroxylated Tyr residue, resulting in an Fe(III)-catecholate with  $\lambda_{\text{max}} = 550$  nm ( $\epsilon = 700$  M<sup>-1</sup> cm<sup>-1</sup>).<sup>14</sup> A better spectroscopic match to the FIH-1 product is the Fe(III)-(hydroxy-Trp) formed by the auto-hydroxylation of TfdA, with  $\lambda_{\text{max}} = 580$  nm ( $\epsilon = 1000$  M<sup>-1</sup> cm<sup>-1</sup>),<sup>15</sup> suggesting that the purple

<sup>a</sup> Department of Chemistry, University of Massachusetts, Amherst, Massachusetts 01003, USA. E-mail: mknapp@chem.umass.edu; Fax: +1 413-545-4490; Tel: +1 413-545-4001

<sup>b</sup> Program in Molecular and Cellular Biology, University of Massachusetts, Amherst, Massachusetts 01003, USA

<sup>c</sup> Department of Polymer Science and Engineering, University of Massachusetts, Amherst, Massachusetts 01003, USA


† Electronic supplementary information (ESI) available: ESI-MS/MS spectra of trypsin-digested purple FIH-1. See DOI: 10.1039/b809099h




**Fig. 1** The UV-vis absorption spectrum of FIH-1 (100  $\mu\text{M}$  in 50 mM HEPES, pH 7.50),  $\text{FeSO}_4$  (500  $\mu\text{M}$ ) and  $\alpha\text{KG}$  (500  $\mu\text{M}$ ). (A) Anaerobic conditions, (B) following exposure to air.

chromophore that was formed by the auto-hydroxylation of FIH-1 contained a hydroxylated Trp residue, HO-Trp. Inspection of the FIH-1 sequence indicated that the Trp and Tyr residues within the active site (Fig. 2) would be located on separate tryptic fragments, suggesting that MS could be used to identify the hydroxylation site.

MS was used to identify the site of hydroxylation in a tryptic digest of FIH-1. The tryptic digest was separated by reverse-phase HPLC and detected *via* ESI-MS analysis performed on an ESI-Q-TOF instrument.† LC-MS/MS analysis of the tryptic digest showed that the tryptic fragments containing Tyr<sup>93</sup> and Tyr<sup>102</sup> were unmodified, while the fragment containing Trp<sup>296</sup> (252–298, 5512.7 Da) appeared at  $m/z = 1379.2$  (unmodified,



**Fig. 2** Aromatic residues within the active site of FIH-1 (PDB 1H2K).<sup>16</sup>



**Fig. 3** ESI-TOF spectrum of the tryptic digest fragment 252–298 from purple FIH-1.

$\text{MH}_4^{4+}$ ) and 1383.2 (+16 Da,  $\text{OMH}_4^{4+}$ ) as  $z = 4+$  ions. Co-elution of modified and unmodified Trp<sup>296</sup> fragments revealed relative intensities of  $\text{MH}_4^{4+} : (\text{OMH}_4^{4+}) \sim 7 : 3$  (Fig. 3).‡

The hydroxylated residue was identified by LC purification of the Trp<sup>296</sup> peptides, followed by direct infusion into the ESI-TOF spectrometer. ESI-MS/MS analysis was performed on the  $z = 4+$  ions for both peptide peaks. The b- and y-ion sequence of the  $\text{MH}_4^{4+}$  ion corresponded to the genetically encoded sequence. In contrast, the b- and y-ion sequence of the  $\text{OMH}_4^{4+}$  ion revealed that the additional O-atom was located on Trp<sup>296</sup> (Table 1). This positively identified the active-site Trp residue as the sole site of O-atom insertion.

The purple chromophore that formed on FIH-1 was identified as an  $\text{Fe(III)-O-Trp}^{296}$  species by the identification of O-atom addition to Trp<sup>296</sup> and its similarity to the blue  $\text{Fe(III)-O-Trp}$  chromophore found in TfdA. While the Trp<sup>296</sup> of FIH-1 is separated in a 1° sequence from the Fe ligands, it is positioned very close (<5 Å) to the Fe center. As C7 of the indole ring of Trp<sup>296</sup> is located closest to the Fe, this may be the site of hydroxylation.

By analogy to the consensus chemical mechanism for normal turnover,<sup>10</sup> we propose that the  $\text{Fe(III)-O-Trp}$  center in FIH-1 is formed by the uncoupled activation of  $\text{O}_2$ , leading to the formation of an  $\text{Fe(IV)=O}$  intermediate in the absence of HIF $\alpha$ . H-atom abstraction, followed by rebound, led to  $\text{HO-Trp}^{296}$  and  $\text{Fe(II)}$ , which, through subsequent oxidation and coordination, formed the observed  $\text{Fe(III)-O-Trp}$  species. As the normal rate of turnover for FIH-1 to hydroxylate HIF $\alpha$  substrates is

**Table 1** Observed y-ions from ESI-MS/MS analysis of the Trp<sup>296</sup> peptide (252–298) by direct infusion and fragmentation of the  $z = 4+$  ion at  $m/z = 1383.2$

Amino acid	y-ion number	Unmodified $m/z$ observed (calc.)	Modified $m/z$ observed (calc.)
T	7		973.48 (973.48)
V	6		872.41 (872.44)
N	5		773.39 (773.37)
F	4		659.35 (659.32)
W	3		512.28 (512.26)
Y	2	310.19 (310.18)	
K	1	147.11 (147.11)	

ca.  $0.24 \text{ s}^{-1}$ ,<sup>18,19</sup> and the auto-hydroxylation occurred on the timescale of hours, auto-hydroxylation would only be kinetically relevant under conditions of low HIF $\alpha$  concentration.

We speculate that the auto-hydroxylation of FIH-1 may comprise an important regulatory feature of physiological hypoxia sensing. Under normoxic conditions, HIF $\alpha$  is rapidly degraded within cells, thereby depleting FIH-1 of its physiological substrate—such conditions would favor uncoupled O<sub>2</sub>-activation. As suggested within the context of TauD and TfdA function,<sup>10</sup> FIH-1 auto-hydroxylation may protect the cell from deleterious effects of reactive oxygen species by serving in a sacrificial role. Alternatively, auto-hydroxylation may serve as a negative feedback mechanism to regulate hypoxia sensing by reducing the activity of FIH-1.

Acknowledgement is made to the University of Massachusetts, the American Cancer Society (#IRG 93-033) and the NIH (GM077413) for funding.

## Notes and references

‡ Experimental details: FIH-1 (10  $\mu\text{M}$ ) was digested by trypsin overnight (37 °C, 50 mM Tris, pH 8.00, 1 mM CaCl<sub>2</sub>). The tryptic digest (30  $\mu\text{l}$  injection) was separated by reverse-phase HPLC, using a CH<sub>3</sub>CN/H<sub>2</sub>O (0.1% formic acid) gradient, over a 150  $\times$  2.1 mm PLRP-S column with a 300 Å pore size and a 3  $\mu\text{m}$  particle size (Polymer Laboratories, Amherst, MA). High resolution MS utilized a Qstar XL hybrid ESI-TOF spectrometer (Applied Biosystems, Inc.) that was set to detect positive ions over the 500–2000  $m/z$  range, and fragment the 3<sup>+</sup>, 4<sup>+</sup> and 5<sup>+</sup> ions of the unmodified peptide (1838.6, 1379.2 and 1103.5  $m/z$ ) and hydroxylated peptide (1843.9, 1383.2 and 1106.7  $m/z$ ). The positive ions of the 252–298 peptide fragment were found at both unmodified (5512.7 Da) and O-atom added (5528.7 Da) masses.

- 1 C. J. Schofield and P. J. Ratcliffe, *Nat. Rev. Mol. Cell Biol.*, 2004, **5**, 343–354.
- 2 K. Guillemin and M. A. Krasnow, *Cell*, 1997, **89**, 9–12.
- 3 P. C. Mahon, K. Hirota and G. L. Semenza, *Genes Dev.*, 2001, **15**, 2675–2686.

- 4 K. S. Hewitson, L. A. McNeill, M. V. Riordan, Y. M. Tian, A. N. Bullock, R. W. Welford, J. M. Elkins, N. J. Oldham, S. Bhattacharya, J. M. Gleadle, P. J. Ratcliffe, C. W. Pugh and C. J. Schofield, *J. Biol. Chem.*, 2002, **277**, 26351–26355.
- 5 D. Lando, D. J. Peet, J. J. Gorman, D. A. Whelan, M. L. Whitelaw and R. K. Bruick, *Genes Dev.*, 2002, **16**, 1466–1471.
- 6 G. L. Semenza, *Science*, 2007, **318**, 62–64.
- 7 S. A. Dames, M. Martinez-Yamout, R. N. De Guzman, H. J. Dyson and P. E. Wright, *Proc. Natl. Acad. Sci. U. S. A.*, 2002, **99**, 5271–5276.
- 8 S. J. Freedman, Z. Y. J. Sun, F. Poy, A. L. Kung, D. M. Livingston, G. Wagner and M. J. Eck, *Proc. Natl. Acad. Sci. U. S. A.*, 2002, **99**, 5367–5372.
- 9 L. A. McNeill, K. S. Hewitson, T. D. Claridge, J. F. Seibel, L. E. Horsfall and C. J. Schofield, *Biochem. J.*, 2002, **367**, 571–575.
- 10 R. P. Hausinger, *Crit. Rev. Biochem. Mol. Biol.*, 2004, **39**, 21–68.
- 11 J. Zhou, M. Gunsior, B. O. Bachmann, C. A. Townsend and E. I. Solomon, *J. Am. Chem. Soc.*, 1998, **120**, 13539–13540.
- 12 J. Zhou, W. L. Kelly, B. O. Bachmann, M. Gunsior, C. A. Townsend and E. I. Solomon, *J. Am. Chem. Soc.*, 2001, **123**, 7388–7398.
- 13 M. L. Neidig, C. D. Brown, K. M. Light, D. G. Fujimori, E. M. Nolan, J. C. Price, E. W. Barr, J. M. Bollinger, C. Krebs, C. T. Walsh and E. I. Solomon, *J. Am. Chem. Soc.*, 2007, **129**, 14224–14231.
- 14 M. J. Ryle, A. Liu, R. B. Muthukumar, R. Y. N. Ho, K. D. Koehntop, J. McCracken, L. Que and R. P. Hausinger, *Biochemistry*, 2003, **42**, 1854–1862.
- 15 A. Liu, R. Y. N. Ho, L. J. Que, M. J. Ryle, B. S. Phenny and R. P. Hausinger, *J. Am. Chem. Soc.*, 2001, **123**, 5126–5127.
- 16 J. M. Elkins, K. S. Hewitson, L. A. McNeill, J. F. Seibel, I. Schlemminger, C. W. Pugh, P. J. Ratcliffe and C. J. Schofield, *J. Biol. Chem.*, 2003, **278**, 1802–1806.
- 17 E. I. Solomon, T. C. Brunold, M. I. Davis, J. N. Kemsley, S. K. Lee, N. Lehnert, F. Neese, A. J. Skulan, Y. S. Yang and J. Zhou, *Chem. Rev.*, 2000, **100**, 235–349.
- 18 K. S. Hewitson, L. A. McNeill, M. V. Riordan, Y. M. Tian, A. N. Bullock, R. W. Welford, J. M. Elkins, N. J. Oldham, S. Bhattacharya, J. M. Gleadle, P. J. Ratcliffe, C. W. Pugh and C. J. Schofield, *J. Biol. Chem.*, 2002, **277**, 26351–26355.
- 19 D. Ehrismann, E. Flashman, D. N. Genn, N. Mathioudakis, K. S. Hewitson, P. J. Ratcliffe and C. J. Schofield, *Biochem. J.*, 2007, **401**, 227–234.